Acetylcholine Elevation Relieves Cognitive Rigidity and Social Deficiency in a Mouse Model of Autism

Golan Karvat and Tali Kimchi

Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel

INTRODUCTION

Autism spectrum disorders (ASD) are defined by behavioral deficits in social interaction and communication, repetitive stereotyped behaviors, and restricted interests/cognitive rigidity. Recent studies in humans and animal-models suggest that dysfunction of the cholinergic system may underlie autism-related behavioral symptoms. Here we tested the hypothesis that augmentation of acetylcholine (ACh) in the synaptic cleft by inhibiting acetylcholinesterase may ameliorate autistic phenotypes. We first administered the acetylcholinesterase inhibitor (AChEI) Donepezil systemically by intraperitoneal (i.p.) injections. Second, the drug was injected directly into the rodent homolog of the caudate nucleus, the dorsomedial striatum (DMS), of the inbred mouse strain BTBR T + tf/J (BTBR), a commonly-used model presenting all core autism-related phenotypes and expressing low brain ACh levels. We found that i.p. injection of AChEI to BTBR mice significantly relieved autism-relevant phenotypes, including decreasing cognitive rigidity, improving social preference, and enhancing social interaction, in a dose-dependent manner. Microinjection of the drug directly into the DMS, but not into the ventromedial striatum, led to significant amelioration of the cognitive-rigidity and social-deficiency phenotypes. Taken together, these findings provide evidence of the key role of the cholinergic system and the DMS in the etiology of ASD, and suggest that elevated cognitive flexibility may result in enhanced social attention. The potential therapeutic effect of AChEIs in ASD patients is discussed.

Keywords: Autism; acetylcholine; dorsomedial striatum; mouse model; donepezil; BTBR
Acetylcholine elevation improves autism-related behaviors

G Karvat and T Kimchi

MATERIALS AND METHODS

Subjects

Male BTBR T + tf/J (BTBR, Jackson Laboratory) and FVB/NJ (FVB, Harlan Laboratories) were housed in groups of 3–5 littermates per cage, in humidity- and temperature-controlled room with reversed 12 h light cycle. Drug administration and surgical procedures started at 7 weeks of age and behavior testing at 8 weeks of age. All experimental procedures were approved by the Institutional Animal Care and Use Committees of the Weizmann Institute of Science.

Drug Treatments

Donepezil hydrochloride monohydrate (Sigma-Aldrich) was applied by either systemic intraperitoneal (i.p.) injection (experiment 1) or stereotactic intracranial injection into the DMS or the ventromedial striatum (VMS) (experiment 2).

Experiment 1: Systemic I.P Injection

For experiment 1, the drug was dissolved in saline (NaCl 0.9%). Mice received daily i.p. injections of 4 ml/kg 7 days before and throughout the whole experiment 30 min before testing. Mice were randomly assigned to three treatment groups of littermates (N = 8/dose): 0.0 (saline, control), 0.3, and 1.0 mg/kg. During the time between drug administration and testing, the mice were held in the testing room. This sub-chronic administration regimen was chosen due to three reasons: (a) future treatment in humans is expected to be chronic, (b) previous studies with the drug (eg, (Van Dam et al, 2005)) utilized similar regimens, and (c) due to the continuation of the behavioral testing over a few days, an acute treatment was not possible. Furthermore, an additional group (N = 8) received 1.0 mg/kg (i.p.) of the drug in a semi-acute fashion, similar to the drug treatment in experiment 2 (see below).

Experiment 2: Stereotactic Intracranial Injection

Cannula implantation. Mice were anesthetized with 6 ml/kg ketamine/xylazine solution, and secured to the stereotactic frame (Kopf). The coordinates of DMS were 1.0 mm anterior to bregma, ±1.4 mm lateral to midline and 3.1 mm ventral to dura. Coordinates of the VMS were: anterior–posterior, +1.0 mm; medial-lateral, ±1.4 mm; and dorsal-ventral, −4.5 mm (Franklin and Paxinos, 1997). Stainless-steel guide cannulae covered with dummy cups extending 1 mm ventrally were implanted at a 15° angle aimed medially, and secured with screws covered with dental acrylic cement. Following the surgery, mice were singly housed and allowed to recover in their home-cages for 10 days, before behavioral testing commenced.

Drug treatment. Donepezil was dissolved in artificial cerebrospinal fluid (aCSF) (in mmol/l: 125 NaCl; 2.5 KCl; 0.5 NaH2PO4; 5 Na2HPO4; 1 MgCl2; 1.2 CaCl, pH 7.3). Seven mice were injected bilaterally with 100 ng Donepezil in 0.5 μl aCSF into the DMS. Two groups were used for control: mice that received 0.5 μl aCSF into the DMS (N = 6) and mice that received 100 ng Donepezil in 0.5 μl aCSF into the VMS (N = 7), as control for site specificity.

Drug microinjection. Each mouse received a bilateral injection 30 min before testing and stayed in the testing room until test onset for acclimation. The injection was carried out via internal cannula that extended 1.0 mm below the guide cannula. Polyethylene FEP tubing (CMA microdialysis) connected the cannulae to 50 μl Hamilton syringes. The syringes were driven by a microinjection pump (Harvard Apparatus). Solutions were injected at a rate of 0.25 μl/min for 2 min. The cannula remained in the guide cannula for 1 min after the injection to allow for diffusion. All mice were injected with aCSF in the third running day.
(see behavioral testing below) for acclimation to procedure and reduction of stress. In each day from the fourth running day until the end of experiment, mice were injected with either aCSF or Donepezil, according to group. A 30 min post-injection test time was chosen based on the results of a previously reported study (Wang and Tang, 1998).

Behavioral testing. The set of autism-related behavior tests was described previously in detail (Karvat and Kimchi, 2012) and consisted of the following: (I) running/jammed wheel series of tests; (II) open-field; (III) repetitive behavior measurement; (IV) male–male social interaction assay; (V) three-chamber sociability assay; and (VI) water T-maze. All experiments took place during the active period of the subjects in the dark (except for the T-maze, which was conducted under white fluorescent lighting) and were recorded by low-light sensitive video cameras under infrared illumination. Behaviors were scored by an experienced evaluator blind to treatment. The experimental procedures are given in the Supplementary Materials and Methods and are described below briefly.

Running/jammed wheel test. Mice were habituated to run on a wheel for 4 days (days Run 1–4). In the 5th and 6th days, the wheel was jammed (days Jam1–2). Comparison of interaction time with the wheel trying to move it in day Jam1 to running duration in day Run4 served as an indicator of ability to adjust to an environmental change. Comparison of day Jam2 to Jam1 served as indicator of memory of the change.

'Social' running wheel test. In the last day of the wheel assay, a stranger mouse was placed in the cage. Social preference was assessed by comparing interaction time with the stranger mouse, initiated by the subject mouse, compared with interaction time with the object (the jammed-wheel).

Open-field test. Subjects were put in the open-field cage for 30 min. Total distance moved and time spent in the central compartment of the cage were measured.

Repetitive behaviors scoring. For repetitive self-grooming measure, subjects were put in a clean, empty cage. For repetitive digging measure, subjects were put in a similar cage covered with ~1 cm corn-cob-bedding. Total repetitive behavior time was scored by an observer.

Male–male social interaction test. Alien ICR male mouse (5 weeks old) was introduced to a cage with the subject mouse. Behaviors scored included duration of sniffing, chasing, mounting, and aggressive attacks.

Three-chamber social approach and social novelty preference test. The test was conducted according to a previously described method (Moy et al, 2007). Following habituation, subject mouse was put in the central compartment of a three-chambered cage, and was allowed to interact with either a wire-cage housing a stranger mouse or an empty wire-cage. In the next trial, the subject had the choice between the already familiar mouse and a novel stranger. Duration of sniffing of each cage was scored.

Acetylcholine elevation improves autism-related behaviors  
G Karvat and T Kimchi

Water T-maze spatial reversal learning test. The test was based on (Dong et al, 2005; Guariglia et al, 2011), and lasted 4 days, 10 trials per day. In the first 2 days, subjects had to learn and remember the arm containing the escape platform in a T-shaped water maze. In the third day, the arm containing the platform was changed. Numbers of correct turns and latency to reach the platform were measured.

Histology: Confirmation of the Injection Site in the Brain

Following the completion of behavioral testing, mice were euthanized and 0.5 µl RhodamineB dye (Sigma-Aldrich) was delivered through each of the guide cannulae. The brains of the mice were removed and stored in a 4% formaldehyde solution at 4°C for 72 h. Using a vibratome (Leica), the brains were sliced into coronal sections (100 µm) and photographed through a binocular. The sections were then examined to determine the placement of the cannula tips and assess the maximal spread.

Statistical Analysis

Data in figures are presented as mean ± SEM. Comparisons between treatment groups were conducted using one-way or two-way repeated measure analysis of variation (ANOVA), with the Tukeys post hoc where appropriate. Statistical significance was set at α<0.05 in the Statistca software (Statsoft, Tulsa, OK), when p<0.05 was considered significant.

RESULTS

Experiment 1

Systemic administration of Donepezil relieved cognitive rigidity in a dose-dependent manner. Mice injected i.p. with Donepezil (0.3 or 1.0 mg/kg) showed a dose-dependent improvement in the ability to adjust to changes in the environment as evaluated by two independent behavioral measures: water T-maze, which tested reversal spatial learning (Figure 1a), and the running/jammed wheel assay, which tested the ability to adjust to a denial of a rewarding activity (Figure 1c).

In the water T-maze, all groups exhibited intact learning and memory capabilities, manifested in a significant improvement in correct turns taken between days 1 and 2 (Figure 1b, F2,21 = 48.8, p<0.001 and p<0.05 for each group in post hoc analysis) with no difference between groups (p>0.7 in each day). In addition, all groups exhibited similar durations to reach the platform in these days (Supplementary Figure S1, p>0.5). However, on day 3, when the arm containing the escape platform was changed, mice treated with Donepezil took significantly more correct turns (F2,21 = 5.9, p<0.01), indicating improved adjustment to change. Post hoc analysis revealed a significant (p<0.01) difference between mice treated with 1.0 mg/kg Donepezil compared with control saline-treated mice, and a smaller yet significant (p<0.05) improvement in the group treated with 0.3 mg/kg (Figure 1b). Furthermore, analysis of preservative errors (ie, number of trials in which the previously reinforced arm is initially chosen until the first
correct turn trial) showed a significant effect of treatment group \(F_{2,21} = 5.8, p < 0.01\). Number of preservative errors of mice treated with 1.0 mg/kg Donepezil \((2.75 \pm 0.63)\) was significantly lower \((p < 0.01)\) than saline-treated mice \((6.38 \pm 0.58)\), and in mice treated with 0.3 mg/kg there was a trend \((p = 0.069)\) toward lower number of preservative errors \((5.38 \pm 0.88)\). A significant effect for treatment groups was found also in latency to reach the platform \(F_{2,21} = 4.7, p < 0.05\), when mice treated with 1.0 mg/kg Donepezil reached the platform faster \((p < 0.05)\) compared with control group. Finally, mice from all treatment groups exhibited similar memory of the environmental change, manifested in improvement in correct turns taken between days 3 and 4 \(F_{1,21} = 236, p < 0.001\) and \(p < 0.001\) for each group in post hoc analysis) with no difference between groups in day 4 \((p > 0.4)\) as well as similar latency to reach the platform \(F_{2,21} = 2.36, p < 0.001\).

In the running/jammed wheel assay, mice from all groups acquired the running habit as demonstrated by shorter latencies to start running on the wheel in days 2–4 compared with the first day \(F_{3,63} = 50.1, p < 0.001\) for each group), with no differences between groups \((p > 0.5)\). Saline-treated control mice, however, exhibited cognitive rigidity as they interacted with the wheel for similar amounts of time whether it was free or jammed (Figure 1e), in line with a previous report with untreated BTBR mice (Karvat and Kimchi, 2012). The ratio between wheel interaction times in the first jammed-day and last running day \(Jam1/Run4\), an indicator of the ability to adjust to an environmental change, was significantly lower in mice treated with Donepezil compared with control mice \(F_{2,21} = 8.6, p < 0.01\), in a dose-dependent manner, indicating improvement in cognitive flexibility in the Donepezil-treated groups. Mice from all treatment groups exhibited similar memory of the change, as indicated by the wheel interaction time ratio of Jam2/Jam1 \((p > 0.8)\).

**Systemic administration of Donepezil improved sociability in a dose-dependent manner.** The effect of i.p. administration of Donepezil on sociability was measured in three separate and complementary tests (Figures 2 and 3): the three-chamber test for social approach and novelty preference, the running wheel test for social interaction preference, and the male–male social interaction test.

In the three-chamber test, all groups spent similar amounts of time in each side-chamber during the habituation trial \((p > 0.9)\) for each group). Number of entries to side chambers was similar as well \((p > 0.5)\), supporting unchanged general activity. In the preference for social approach trial (Figure 2a), however, a significant interaction between stimulus (object or stranger) and Donepezil dosage was found \((F_{2,21} = 8.7, p < 0.01)\). While saline-treated mice showed no preference of the stranger \((p = 1.0)\),
Figure 2  Intraperitoneal (i.p.) administration of Donepezil improved sociability in a dose-dependent manner. BTBR mice were injected i.p. with Donepezil (0.3 or 1.0 mg/kg) or saline (0.0 mg/kg) for 7 days before testing and 30 min before each testing day. (a) Scheme of the three-chamber social preference test. One cage contained a stranger mouse (stranger cage) and the other was left empty (empty cage). (b) Sniffing durations of each wire cage. (c) Social preference index, calculated as (time with stranger) / (time with stranger + time with empty cage) x 100 – 50. (d) Scheme of the ‘social’ running/jammed wheel assay. The preference of interaction with a stranger over an object was measured by comparing interaction time with a stranger mouse to interaction time with the previously-rewarding jammed-wheel (e). Social preference index (f) was calculated as (time with stranger) / (time with stranger + time with jammed wheel) x 100 – 50. (g) The male–male interaction test. Cumulative durations of sniffing and chasing the intruder mouse, as well as total social interactions, within a 15-min period. Data are presented as mean ± SEM. *p = 0.09, *p < 0.05, **p < 0.01, ***p < 0.001, n.s: not significant. N = 8/dose.

Figure 3  Intraperitoneal (i.p.) administration of Donepezil tended to improve social memory (preference for social novelty). BTBR mice were injected i.p. with Donepezil (0.3 or 1.0 mg/kg) or saline (0.0 mg/kg) for 7 days before testing and 30 min before each testing day. (a) Scheme of the three-chamber social novelty preference test. An unfamiliar stranger mouse (novel stranger) was put in the previously empty wire-cage. (b) Sniffing durations of the wire cage containing the novel stranger or familiar mouse. (c) Social novelty preference index, calculated as (time with novel stranger) / (time with novel stranger + time with familiar mouse) x 100 – 50. Data are presented as mean ± SEM. *p = 0.12, *p < 0.05, **p < 0.01, n.s: not significant. N = 8/dose.
mice treated with 0.3 mg/kg showed a trend toward social preference ($p = 0.094$), and mice treated with 1.0 mg/kg Donepezil showed a significant preference of the stranger mouse ($p < 0.001$). The dose-dependent improvement was evident also in analysis of the social index (Figure 2c, $F_{2,21} = 12.5, p < 0.001$), as the 1.0 mg/kg group reached significantly ($p < 0.001$) higher scores than the control group, and the 0.3 mg/kg improved to a lesser extent, yet significantly ($p < 0.05$).

Systemic Donepezil administration also significantly enhanced preference for social interaction in the ‘social’ running wheel assay (Figure 2d). A significant correlation between stimulus (stranger mouse or jammed-wheel) and dosage was found (Figure 2e, $F_{2,21} = 3.5, p < 0.05$), as control mice did not significantly prefer the stranger mouse ($p > 0.35$), mice treated with 0.3 mg/kg showed a significant preference ($p < 0.01$), and the highest preference was found in mice treated with the highest dose ($p < 0.001$). A dose-dependent improvement was also found in analysis of the social preference index (Figure 2f, $F_{2,21} = 5.3, p < 0.05$), when only mice treated with 1.0 mg/kg Donepezil exhibited significantly higher scores than the control mice.

In the male–male social interaction test (Figure 2g), 1.0 mg/kg Donepezil-treated mice spent significantly ($p < 0.05$) more time in sniffing and chasing, as well as total social interaction, compared with saline-treated mice. The difference between the 0.3 mg/kg group and both other groups was not found significant in any measurement. To note, all mice spent negligible amounts of time ($< 1 \text{s } \text{on average}$) in mounting and aggressive behaviors.

Finally, an improvement was found in the Donepezil-treated groups in the preference for novel social stimulus, as measured in the three-chamber test (Figure 3a). While saline-treated mice did not significantly prefer the novel stranger (Figure 3b, $p > 0.4$), both doses of the drug resulted in a significant preference for social novelty (Figure 3b). Furthermore, a trend toward improvement in the social novelty preference index was found (Figure 3c, $F_{2,21} = 2.3, p = 0.12$). To note, measurement of total time in chamber yielded a significant preference to the chamber containing the novel stranger for all treatment groups ($F_{3,21} = 126.01, p < 0.001$), with no interaction between treatment group and time in chamber ($F_{2,21} = 1.1, p = 0.36$).

**Experiment 2**

Donepezil administration into the DMS, but not VMS, rescued cognitive rigidity and social deficiency. We next investigated whether intracranial microinjection of Donepezil into the DMS can improve the above described autism-related behaviors. We compared the behavioral performance in the running/jammed wheel assays of a mouse group that received Donepezil into the DMS with two control mouse groups: (a) mouse group that received aCSF into the DMS and (b) mouse group that received Donepezil into the VMS (Figure 4 and Supplementary Figure S2).

Mice from each group acquired the running habit as demonstrated by shorter latencies to start running on the wheel in days 2–4 compared with the first day (Figure 5a, $F_{3,51} = 141.2, p < 0.001$ for each group), with no differences between groups ($p > 0.8$). Injection of Donepezil into the DMS, however, resulted in a significant improvement in adjustment to change, as reflected from a significantly lower Jam1/Run4 interaction time ratio (Figure 5b, $F_{2,17} = 10.8, p < 0.001$) compared with each control group ($p < 0.01$ in post hoc analysis).

Social preference was also significantly improved by injection of Donepezil into the DMS, but not into the VMS or aCSF into the DMS. While mice injected with aCSF into the DMS and Donepezil into the VMS spent similar amounts of time in interaction with the stranger mouse or the jammed-wheel (Figure 5c, $p > 0.9$), mice that received Donepezil into the DMS spent significantly more time with the stranger over interacting with the jammed-wheel ($p < 0.01$). The behavioral difference between groups was reflected in a significant interaction between treatment and stimulus (jammed-wheel or stranger mouse, $F_{2,17} = 9.6, p < 0.01$). Social preference index of the mouse group that received Donepezil injection into the DMS was significantly higher than both control groups as well (Figure 5d). The effect of treatment was found significant ($F_{1,17} = 9.6, p < 0.01$), as the Donepezil to the DMS group presented significantly higher scores than both control groups (Figure 5d, $p < 0.01$ in post-hoc analysis).

No effect on repetitive behaviors. No significant differences were found in repetitive self-grooming and bedding-digging durations, whether mice were treated systemically...
Control tests. Donepezil-treated mice had slightly higher running duration (Supplementary Figure S4) in comparison with the control group mice. This difference may indicate an improvement in cognitive flexibility reflected in weighing the possible stimuli in the environment and investing more time with the rewarding stimulus, as long as it is rewarding. Alternatively, the difference may be the result of changed locomotion or anxiety levels. Hence, to better define whether Donepezil treatment had effect on locomotion and anxiety-related behaviors, we performed the open-field test on a second cohort of control and drug-treated BTBR mice. No differences between treatment groups were found in general activity (distance moved) (Supplementary Figure S5a, \( p > 0.7 \)) or anxiety-related behaviors (time spent in the central compartment of the open-field) (Supplementary Figure S5b, \( p > 0.9 \)).

We also tested the effects of the drug treatment on the behavior of a second mouse strain—the FVB. This strain is considered neurotypical and used as a control mouse model to BTBR (Bolivar et al., 2007; Ellegood et al., 2013a; Moy et al., 2007). FVB mice were tested in the running/jammed wheel test using the exact procedure in which BTBR mice were tested, both systemically and intracranially. Following systemic administration, FVB mice from all treatment groups ran on the wheel similar amounts of time (Supplementary Figure S6a, \( p > 0.4 \)) and exhibited similar adjustment to change (Supplementary Figure S6b, \( p > 0.4 \)).

Furthermore, similar to systematic drug administrations, intracranially microinjected FVB mice (Supplementary Figure S6c) from all treatment groups ran on the wheel similar amounts of time (Supplementary Figure S6d, \( p > 0.7 \)) and exhibited similar adjustment to change (Supplementary Figure S6e, \( p > 0.3 \)). Lastly, no difference was found between the control and drug-treated FVB mice in the open-field test (\( p > 0.7 \)). Taken together, treatment with the tested doses of Donepezil did not appear to affect locomotion or anxiety-related behaviors in BTBR mice nor did it affect the neurotypical behaviors of the FVB control strain.

DISCUSSION

The major finding of this study is that elevation of ACh levels led to a significant improvement in cognitive rigidity, social preference and social interactions, all core symptoms in ASD patients. Systemic treatment with the AChEI Donepezil rescued the autistic-like phenotype in independent and complementary behavioral tests conducted on a well-described mouse model of autism. Similar effects were achieved by direct microinjection into the dorsomedial striatum but not into the ventromedial-striatum.
The effect of the AChEI Donepezil on cognitive functions was previously examined extensively on neurotypical mice and rats or animal models of Alzheimer disease (Yoo et al., 2007), but, to our knowledge, never on ASD animal models. For example, the positive behavioral effect of the drug was shown with respect to attention, learning, and memory (reviewed in (Yoo et al., 2007)). In addition, Donepezil treatment was demonstrated to increase spontaneous alternations (Spowart-Manning and van der Staay, 2004), improve reversal learning in spatial-tasks (Dong et al., 2005), and relieve social memory deficiency (Riedel et al., 2009).

These reports fit well with our findings. Systemic administration of the drug in the BTBR mouse model of autism improved cognitive flexibility, comparable to the results obtained in spatial reversal learning tests after administration of Donepezil in doses similar to the current study (Yoo et al., 2007). In addition, our results in the social novelty test of untreated BTBR mice agrees with a previous report (Moy et al., 2007), in which these mice spent significantly more time in the chamber containing the novel stranger, but not in physical contact with it. Similarly to (Riedel et al., 2009), treatment with Donepezil improved social memory. To the best of our knowledge, the current study is the first to demonstrate the positive effect of the drug on different aspects of sociability including social preference and male-female social interactions, in a mouse model of autism.

The results obtained from direct infusion of the AChEI Donepezil into the DMS agree with previous studies as well. The group of Ragozzino showed in a series of experiments that disruption of ACh function in this area results in inability of behavioral shift (McCool et al., 2008; Ragozzino and Choi, 2004). Here, we showed that increment of available ACh in the DMS rescued the cognitively rigid behaviors. Surprisingly, the possible influence of attention and cognitive shift attributed to the cholinergic system and the striatum on social behavior was never thoroughly tested. In the neuronal level, thalamo-cortical cholinergic projections have been shown to modulate the excitatory neurotransmitter glutamate (Mesulam et al., 1983). On the other hand, striatal cholinergic interneurons change their firing-pattern in response to environmental changes, and modulate the activity of the spiny projections neurons (Goldberg and Reynolds, 2011). The projection neurons, in turn, are the source of the γ-aminobutyric acid (GABA)ergic inhibitory outcome of the striatum (Graybiel et al., 1994). Within the cortex, ACh has distinct excitatory and inhibitory effects on different layers, depending on receptor-type distribution (Eggermann and Feldmeyer, 2009). Additionally, because ACh regulates CNS development, including growth, differentiation, and plasticity, it has an impact on the representational differentiation of excitatory and inhibitory synapses (Lauder and Schambra, 1999). Therefore, ACh has an important role in modulating the balance between excitation and inhibition (E/I) in the brain. Autism has been hypothesized to arise from disrupted E/I balance within neuronal microcircuity (Rubenstein and Merzenich, 2003), and recently it was demonstrated that increased inhibition moderately ameliorated the social behavior deficits in mice subjected to elevation of cellular E/I balance (Yizhar et al., 2011).

The BTBR strain is a promising model to study the importance of striatal ACh modulation of the E/I balance and its effect on autism. Recent studies demonstrated that low levels of ACh (McTighe et al., 2013) and reduction in striatal size (Ellegood et al., 2013b) accompany the aberrant behavior of this strain. Additionally, recent indirect evidence suggests E/I imbalance involvement in BTBR symptomology, as pharmacological modulation of glutamatergic synapses rescues these behaviors (Silverman et al., 2012). Hence, our findings suggest of interplay between ACh imbalance and endophenotypes of ASD associated with social deficiencies and cognitive flexibility. Future investigation of the modulatory effect of ACh on the E/I balance in autism-related mouse models should be performed to further elucidate the role of ACh action in the CNS in ASD symptoms, specifically related to attention, flexibility, and their association with social preference. This may potentially open a new venue for therapeutic interventions in ASD patients.

ACKNOWLEDGEMENTS

We thank M Dayan, L Edry, Y Sofer, N Barak, and L Khalfin for their assistance in conducting the experiments. We also

FUNDING AND DISCLOSURE

This work was supported by the Nella and Leon Benoziyo Center, Kekst Family Institute for Medical Genetics, and Jonathan and Joan Birnbach foundation (TK). The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank M Dayan, L Edry, Y Sofer, N Barak, and L Khalfin for their assistance in conducting the experiments. We also
thank A Weissbrod for his assistance with designing and building the experimental set-up.

REFERENCES


Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)